Author Archive | wpadmin

IMPAACT P1078 Begins in Seke North and St. Mary’s

November and December 2014 were exciting months for Seke North and St. Mary’s CRSs, as they began screening and enrollment into IMPAACT P1078. This study is looking to see if INH (Isonizaid, a medication used to treat or prevent tuberculosis) protects HIV-infected pregnant women and their infants from contracting tuberculosis, and if starting INH during […]

Continue Reading 0

NIH-sponsored study identifies superior drug regimen for preventing mother-to-child HIV transmission

For HIV-infected women in good immune health, taking a three-drug regimen during pregnancy prevents mother-to-child HIV transmission more effectively than taking one drug during pregnancy, another during labor and two more after giving birth, an international clinical trial has found.  The ongoing PROMISE (Promoting Maternal-Infant Survival Everywhere) study also has found that one triple-drug regimen […]

Continue Reading 0
HPTN 076 News Photo 3a

HPTN 076: Injectable PrEP

Client-centered models of HIV prevention for women which employ Pre Exposure Prophylaxis (PrEP) examine both drug effectiveness but also drug delivery. It has become critical to understand whether available delivery options are likely to be utilized given individual risk, preference and lifestyle. Most frequently offered as a pill, vaginal film, vaginal ring or gel, injectable […]

Continue Reading 0
hvtn site visit

James Kublin, MD, MPH, Executive Director of HVTN, Visits Harare

HIV Vaccine Trials Network (HVTN) Executive Director, James Kublin, MD, MPH, lead a one-day training on 3 October 2014, in Harare, aimed at orienting Zimbabwe national regulators to the work of the HVTN, the P5 Initiative in Southern Africa, and Phase I clinical trials the network is planning for implementation in the region.  The P5 […]

Continue Reading 0

1994 – 2014: UZCHS-CTRC Celebrates 20 Years of Cutting Edge Research in Collaboration with UCSF

2014 marked the 20th Anniversary of UZCHS-CTU and collaborations with UCSF in Harare, Zimbabwe.  Since its inception in 1994, our studies have helped to shape national and global responses to the HIV/AIDS pandemic, and have defined policies and standards regarding the course of HIV acquisition, prevention, treatment, and care. Some examples include groundbreaking research in […]

Continue Reading 0


Linking HIV prevention strategies to contraception has a significant potential for public health benefit.  However, many large observational studies to date have indicated an association between the use of combined oral contraceptives or depot medroxyprogesterone acetate and HIV acquisition and transmission.  To date, little research has been designed to try and explain if hormonal contraceptive […]

Continue Reading 0

UZ-CTRC-Clinical Trials Unit Awarded Continued Funding Into 2021

UZ-CTRC, in collaboration with UCSF, has been awarded continued Clinical Trials Unit (CTU) funding from the US National Institute of Allergy and Infectious Diseases (NIAID) to continue conducting high quality HIV treatment and prevention studies through 2021. The CTU will continue to operate seven clinical research sites, which operate under four NIAID sponsored research networks: […]

Continue Reading 0